If whole-genome sequencing ever becomes a common part of treating patients, as is expected by many, some tricky ethical and privacy-related problems may arise, most notably questions about what should be done about incidental findings and malevolent things doctors find in the genome that have no treatment.

At Washington University in St. Louis this week, at a global center of genomic medicine, a few experts met in a panel discussion to sift around a bit through the morass of ethical questions whole-genome sequencing might stir up when it does hit the clinic.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Related Posts

In Science this week: swapping yeast genes with human orthologs to study conservation of function, and more.

Hong Kong is using DNA phenotyping to shame litterers.

A study appearing in Cell suggests some metastatic castration-resistant prostate cancer patients could benefit from PARP inhibitor therapy.

NIH's Francis Collins writes that scientific advances are poised to help populations all over the world, but more scientists are needed to keep the momentum.